1
|
Sherban A, Raanani P, Gurion R, Wolach O, Gafter-Gvili A. Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis. Leuk Res 2022; 113:106773. [DOI: 10.1016/j.leukres.2021.106773] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2021] [Revised: 12/12/2021] [Accepted: 12/30/2021] [Indexed: 10/19/2022]
|
2
|
Vassilakopoulos T, Ferhanoglu B, Horowitz N, Mellios Z, Kaynar L, Zektser M, Symeonidis A, Piperidou A, Kalpadakis C, Akay OM, Atalar AC, Katodritou E, Leonidopoulou T, Papageorgiou S, Tadmor T, Gutwein O, Karakatsanis S, Ganzel C, Karianakis G, Isenberg G, Gainaru G, Vrakidou E, Palassopoulou M, Ozgur M, Siakantaris M, Paydas S, Tsirigotis P, Tsirogianni M, Hatzimichael E, Tuglular T, Chatzidimitriou C, Megalakaki E, Kanellias N, Zikos P, Koumarianou A, Gafter‐Gvili A, Angelopoulou M, Karmiris T, Gurion R. RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): REAL‐LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES. Hematol Oncol 2021. [DOI: 10.1002/hon.76_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
3
|
Kalakonda N, Cavallo F, Follows G, Goy A, Vermaat J, Casasnovas O, Lavee O, Maerevoet M, Zijlstra J, Bakshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho J, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos T, Warzocha K, Oluyadi A, McCarthy D, Ma X, Corona K, Shah J, Van Den Neste E, Canales M. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2019. [DOI: 10.1002/hon.31_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - F. Cavallo
- Molecular Biotechnology and Health Sciences; Aziena Ospedaliero - Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - G. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital; Cambridge United Kingdom
| | - A. Goy
- Oncology; Hackensack University Medical Center; Hackensack United States
| | - J. Vermaat
- Hematology; Leiden University Medical Center; Leiden Netherlands
| | | | - O. Lavee
- Hematology; St. Vincent's Hospital Sydney; Darlinghurst Australia
| | - M. Maerevoet
- Hematology; Service Hématologie, Institut Bordet; Bruxelles Belgium
| | - J. Zijlstra
- Hematology; Amsterdam UMC; Amsterdam Netherlands
| | - S. Bakshi
- Medical Oncology; Dr. B. R. A. Institute Rotary Cancer Hospital; New Delhi India
| | - R. Bouabdallah
- Oncology/Hematology; Institut Paoli-Calmettes; Marseille France
| | - S. Choquet
- Hematology; Hospital Pitie Salpetriere; Paris France
| | - R. Gurion
- Hematology; Rabin MC; Petah Tiqwa Israel
| | - B. Hill
- Hematology and Medical Oncology; Cleveland Clinic Main Campus; Cleveland United States
| | - U. Jaeger
- Medicine I; Medical University of Vienna; Vienna Austria
| | - J. Sancho
- Clinical Hematology; Hospital Germans Trias i Pujol; Barcelona Spain
| | - M. Schuster
- Medicine; Stony Brook University; Stony Brook United States
| | | | - F. De la Cruz
- Hematology; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - M. Egyed
- Hematology; Teaching Hospital Mór Kaposi; Kaposvár Hungary
| | - S. Mishra
- Medical Oncology; Institute of Medical Sciences & SUM Hospital; Bhubaneswar India
| | | | | | - K. Warzocha
- Hematology; Instytut Hematologii i Transfuzjologii; Warszawa Poland
| | - A. Oluyadi
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - D. McCarthy
- Clinical Operations; Karyopharm Therapeutics Inc.; Newton United States
| | - X. Ma
- Biostatistics; Karyopharm Therapeutics Inc.; Newton United States
| | - K. Corona
- Medical Affairs; Karyopharm Therapeutics Inc.; Newton United States
| | - J. Shah
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - E. Van Den Neste
- Hematology; Cliniques Universitaires Saint-Luc; Brussels Belgium
| | - M. Canales
- Medicine; Hospital Universitario La Paz; Madrid Spain
| |
Collapse
|
4
|
Pasvolsky O, Rozental A, Raanani P, Gafter-Gvili A, Gurion R. R-CHOP VS. R-CHOP+X FOR NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Hematol Oncol 2019. [DOI: 10.1002/hon.95_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- O. Pasvolsky
- Institute of Hematology; Beilinson Hospital; Petah Tikva Israel
| | - A. Rozental
- Institute of Hematology; Beilinson Hospital; Petah Tikva Israel
| | - P. Raanani
- Institute of Hematology; Beilinson Hospital; Petah Tikva Israel
| | - A. Gafter-Gvili
- Institute of Hematology; Beilinson Hospital; Petah Tikva Israel
| | - R. Gurion
- Institute of Hematology; Beilinson Hospital; Petah Tikva Israel
| |
Collapse
|
5
|
Abadi U, Peled L, Rotman-Pikielny P, Raanani P, Ellis M, Rozovski U, Gurion R. PREVALENCE AND CLINICAL SIGNIFICANCE OF HYPERCALCEMIA AT DIAGNOSIS IN DIFFUSE LARGE B CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.90_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- U. Abadi
- Hematology; Meir Medical Center; Kfar Saba Israel
| | - L. Peled
- Department of Medicine; Sackler School of Medicine, Tel Aviv University; Tel Aviv Israel
| | | | - P. Raanani
- Hematology; Davidoff Cancer Center, Rabin Medical Center; Petah Tikva Israel
| | - M.H. Ellis
- Hematology; Meir Medical Center; Kfar Saba Israel
| | - U. Rozovski
- Hematology; Davidoff Cancer Center, Rabin Medical Center; Petah Tikva Israel
| | - R. Gurion
- Hematology; Davidoff Cancer Center, Rabin Medical Center; Petah Tikva Israel
| |
Collapse
|
6
|
Yeshurun M, Vaxman I, Shargian L, Yahav D, Bishara J, Pasvolsky O, Wolach O, Lahav M, Gurion R, Magen H, Vidal L, Herscovici C, Peck A, Moshe M, Sela-Navon M, Naparstek E, Raanani P, Rozovski U. Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. Clin Microbiol Infect 2017; 24:749-754. [PMID: 29208561 DOI: 10.1016/j.cmi.2017.11.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Revised: 11/14/2017] [Accepted: 11/22/2017] [Indexed: 11/19/2022]
Abstract
OBJECTIVES We aimed to study whether ciprofloxacin prophylaxis reduces infectious complications in patients undergoing autologous haematopoietic cell transplantation (AHCT). METHODS This is a quasi-experimental, retrospective, before-after study. We compared the incidence of bacterial-related complications among 356 patients with multiple myeloma (MM) (n = 202) and lymphoma (n = 154) who underwent AHCT with (n = 177) or without (n = 179) ciprofloxacin prophylaxis between 03/2007 and 10/2012 and between 10/2012 and 07/2016, respectively, at a single centre. RESULTS Febrile neutropaenia, bacteraemia, and pneumonia were significantly more common among patients who underwent AHCT during the second study period and did not receive antibacterial prophylaxis compared with patients who underwent AHCT during the first study period and received antibacterial prophylaxis (89.9% (161/179) vs. 83.1% (147/177), difference 6.9%, 95% CI 0-14.1%, P = 0.002; 15.1% (27/179) vs. 4.5% (8/177), difference 10.6%, 95% CI 4.4-16.9%, p < 0.0001; 12.3% (22/179) vs. 6.2% (11/177), difference 6.1%, 95% CI 0-12.3%, p = 0.04, respectively). The number-needed-to-treat to prevent one episode of bacteraemia, pneumonia, and febrile neutropaenia was 8.6, 8.5, and 13.7, respectively. Patients with ciprofloxacin prophylaxis had higher rates of ciprofloxacin-resistant bacteraemia (62.5% (5/8) vs. 18.5% (5/27), difference 44%, 95% CI 7-70%, p = 0.01). In multivariate analysis, ciprofloxacin prophylaxis significantly decreased the odds of bacteraemia (OR 0.19, 95% CI 0.07-0.52; p < 0.0001) and pneumonia (OR 0.37, 95% CI 0.16-0.85, p = 0.02). CONCLUSION According to our single-centre experience, patients with MM and lymphoma undergoing AHCT may benefit from antibacterial prophylaxis with ciprofloxacin.
Collapse
Affiliation(s)
- M Yeshurun
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
| | - I Vaxman
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - L Shargian
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - D Yahav
- Infectious Diseases Unit, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - J Bishara
- Infectious Diseases Unit, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - O Pasvolsky
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - O Wolach
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - M Lahav
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - R Gurion
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - H Magen
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - L Vidal
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - C Herscovici
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - A Peck
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel
| | - M Moshe
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel
| | - M Sela-Navon
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel
| | - E Naparstek
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - P Raanani
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - U Rozovski
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
7
|
Rozental A, Gafter-Gvili A, Vidal L, Raanani P, Gurion R. The role of maintenance therapy in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Rozental
- Hematology Division; Davidoff Cancer Center, Rabin Medical Center; Petah-Tikva Israel
| | - A. Gafter-Gvili
- Hematology Division; Davidoff Cancer Center, Rabin Medical Center; Petah-Tikva Israel
| | - L. Vidal
- Hematology Division; Davidoff Cancer Center, Rabin Medical Center; Petah-Tikva Israel
| | - P. Raanani
- Hematology Division; Davidoff Cancer Center, Rabin Medical Center; Petah-Tikva Israel
| | - R. Gurion
- Hematology Division; Davidoff Cancer Center, Rabin Medical Center; Petah-Tikva Israel
| |
Collapse
|
8
|
Amitai I, Gurion R, Vidal L, Dann E, Raanani P, Gafter-Gvili A. PET-CT-adapted therapy for advanced Hodgkin lymphoma: A systematic review of the literature. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- I. Amitai
- Institute of Hematology; Rabin Medical Center; Petah Tikva Israel
| | - R. Gurion
- Institute of Hematology; Rabin Medical Center; Petah Tikva Israel
| | - L. Vidal
- Institute of Hematology; Rabin Medical Center; Petah Tikva Israel
| | - E.J. Dann
- Department of Hematology and Bone Marrow Transplantation; Rambam Health Care Campus; Haifa Israel
| | - P. Raanani
- Institute of Hematology; Rabin Medical Center; Petah Tikva Israel
| | - A. Gafter-Gvili
- Institute of Hematology; Rabin Medical Center; Petah Tikva Israel
| |
Collapse
|
9
|
Gurion R, Bernstein H, Vidal L, Raanani P, Gafter-Gvili A. THE VALUE OF PET/CT IN DETECTING BONE MARROW INVOLVEMENT IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- R. Gurion
- Hematology Institute; Rabin Medical Center; Petach Tikva Israel
| | - H. Bernstein
- Department of Nuclear Medicine; Rabin Medical Center; Petach Tikva Israel
| | - L. Vidal
- Hematology Institute; Rabin Medical Center; Petach Tikva Israel
| | - P. Raanani
- Hematology Institute; Rabin Medical Center; Petach Tikva Israel
| | - A. Gafter-Gvili
- Hematology Institute; Rabin Medical Center; Petach Tikva Israel
| |
Collapse
|
10
|
Atzmony L, Amitay-Laish I, Gurion R, Shahal-Zimra Y, Hodak E. Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single-centre experience. J Eur Acad Dermatol Venereol 2015; 29:2382-9. [DOI: 10.1111/jdv.13243] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2015] [Accepted: 05/07/2015] [Indexed: 11/29/2022]
Affiliation(s)
- L. Atzmony
- Department of Dermatology; Rabin Medical Center; Beilinson Hospital; Petach Tikva Israel
| | - I. Amitay-Laish
- Department of Dermatology; Rabin Medical Center; Beilinson Hospital; Petach Tikva Israel
- Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv Israel
| | - R. Gurion
- Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv Israel
- Hematology Institute; Davidoff Cancer Center; Rabin Medical Center; Beilinson Hospital; Petach Tikva Israel
| | - Y. Shahal-Zimra
- Hematology Laboratory; Rabin Medical Center; Beilinson Hospital; Petach Tikva Israel
| | - E. Hodak
- Department of Dermatology; Rabin Medical Center; Beilinson Hospital; Petach Tikva Israel
- Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv Israel
| |
Collapse
|
11
|
Gurion R, Tangpricha V, Yow E, Schanberg LE, McComsey GA, Robinson AB. A5.20 Low vitamin D status is associated with avascular necrosis: an atherosclerosis prevention in paediatric lupus erythematosus substudy. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-207259.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
12
|
Gurion R, Sabella C, Zeft AS. Fever and rash in children: important diagnostic considerations. Minerva Pediatr 2013; 65:575-585. [PMID: 24217627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The association of fever with illness has been known for years. A febrile child may have rash, and physicians need to know when this symptom combination is a benign versus a pathologic clinical presentation. In other terms, potential etiologies are either infectious or non-infectious. With scrupulous, methodical history taking and careful, serial physical examination, the treating physician will find hints to assess and solidify an appropriate diagnosis, and chose an appropriate treatment.
Collapse
Affiliation(s)
- R Gurion
- Pediatric Rheumatology Fellow, Rainbow Babies and Children's Hospital Cleveland, OH, USA -
| | | | | |
Collapse
|
13
|
Gurion R, Lehman TJA, Moorthy LN. Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam 2011; 2012:271569. [PMID: 22235382 PMCID: PMC3253447 DOI: 10.1155/2012/271569] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2011] [Accepted: 09/06/2011] [Indexed: 12/14/2022] Open
Abstract
Systemic juvenile idiopathic arthritis (sJIA) constitutes a small part of juvenile idiopathic arthritis (JIA), yet has a disproportionally higher rate of mortality. Despite being grouped under JIA, it is considered to be a multifactorial autoinflammatory disease. The objective of this paper is to review the epidemiology, pathogenesis, genetics, clinical manifestations, complications, therapy, prognosis, and outcome of sJIA. The presentation and clinical manifestations of sJIA have not changed much in the past several decades, but the collective understanding of the pathogenesis and the development of new targeted therapies (particularly the biologic agents) have transformed and improved the disease outcome for children with sJIA.
Collapse
Affiliation(s)
- R. Gurion
- Division of Pediatric Rheumatology, Rainbow Babies & Children's Hospital, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA
| | - T. J. A. Lehman
- Division of Pediatric Rheumatology, Hospital for Special Surgery and Clinical Pediatrics Weill Medical Center, Cornell University, 535 E 70 St, New York, NY 10021, USA
| | - L. N. Moorthy
- Division of Pediatric Rheumatology, Department of Pediatrics, University of Medicine and Dentistry of NJ-Robert Wood Johnson Medical School, 89 French Street, New Brunswick, NJ 08901, USA
| |
Collapse
|
14
|
Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, Shpilberg O. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - systematic review and meta-analysis (Reply to Kumar et al. and to Herbst et al.). Haematologica 2010. [DOI: 10.3324/haematol.2009.020420] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|